Literature DB >> 14611816

Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix.

Lars Bryngelson Ohlsson1, Laura Varas, Christian Kjellman, Klaus Edvardsen, Magnus Lindvall.   

Abstract

A preformed gelatin matrix containing adherent rat colon carcinoma cells was transplanted subcutaneously into rats to analyze the outgrowth of the tumor and the inflammatory response. The gelatin matrix simplifies the precise localization of the tumor cells early after implantation and allows the gelatin piece with a growing tumor to be dissected for analysis in vitro, after various times in vivo. The immortalized mesenchymal progenitor cell line MPC1cE was cocultured with rat colon carcinoma cells in vivo in gelatin matrix. The mesenchymal progenitor cells inhibited the outgrowth of the rat colon carcinoma and a complete inhibition was seen if the number of mesenchymal progenitor cells were at least equal to the number of tumor cells. The mixture of tumor cells and mesenchymal progenitor cells induced more infiltration of monocytes and granulocytes than tumor cells or mesenchymal progenitor cells alone. Infiltration of T cells and CD31+ endothelial cells correlated to the presence of tumor cells and not to mesenchymal progenitor cells. These findings suggest that tumor cell culture in vivo in a gelatin matrix is effective for early localization of tumor cells in vivo and that mesenchymal progenitor cells effectively inhibit the growth of the tumor cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14611816     DOI: 10.1016/j.yexmp.2003.06.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  59 in total

Review 1.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

Review 2.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  Mesenchymal stem cells: the fibroblasts' new clothes?

Authors:  Muzlifah A Haniffa; Matthew P Collin; Christopher D Buckley; Francesco Dazzi
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 4.  [Therapeutic application of mesenchymal stromal cells in autoimmune disease: rationale and initial clinical experience].

Authors:  G Keysser; L Müller; M Schendel; H-J Schmoll
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

Review 5.  Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?

Authors:  Martha L Arango-Rodriguez; Fernando Ezquer; Marcelo Ezquer; Paulette Conget
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 6.  Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy.

Authors:  Parisa Lotfinegad; Karim Shamsasenjan; Aliakbar Movassaghpour; Jafar Majidi; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2013-12-23

Review 7.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

Review 8.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

9.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

10.  Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.

Authors:  Erika L Spaeth; Jennifer L Dembinski; A Kate Sasser; Keri Watson; Ann Klopp; Brett Hall; Michael Andreeff; Frank Marini
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.